R Contains Benzene Ring Patents (Class 514/617)
  • Patent number: 11439607
    Abstract: A method is disclosed of treating pain with senicapoc, a potent Ca2+-activated K+ channel, KCa3.1 antagonist in CNS-resident microglia. Senicapoc is shown to cause in a decrease of IL-1? and NO release from microglia cells vivo and in vitro. Because of contribution of KCa3.1 to neuropathological processes, senicapoc is useful in the treatment of chronic, neuropathic, visceral, and inflammatory pain and the reversal of tactile allodynia.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: September 13, 2022
    Assignee: Paracelsus Neuroscience I, LLC
    Inventors: Roland Staal, Thomas Möller
  • Patent number: 11434190
    Abstract: Disclosed are compounds of a formula provided herein that show efficacy in the inhibition of SOX18 protein activity, and in particular with respect to the ability of SOX18 to bind DNA and/or particular protein partners. Further, methods of treating angiogenesis- and/or lymphangiogenesis-related diseases, disorders or conditions, such as cancer metastasis and vascular cancers, are provided herein.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: September 6, 2022
    Assignee: THE UNIVERSITY OF QUEENSLAND
    Inventors: Mathias Francois, Johannes Zuegg, Jeroen Overman, Sreeman Kumar Mamidyala, Angela Aguslyarti Salim, Frank Roger Fontaine, Matthew Allister Cooper, Robert John Capon, Avril Alexis Barbara Robertson
  • Patent number: 11375712
    Abstract: The present invention relates to an agrochemical aqueous suspension concentrate comprising a pesticide in the form of pesticide particles and at least 5 wt % of an adjuvant dissolved in the aqueous phase, wherein the adjuvant is of the formula (I) as defined herein. The invention also relates to the adjuvant as defined in formula (I). Furthermore, the invention relates to a process for the preparation of the suspension concentrate by contacting water, the pesticide, and the adjuvant. The present invention further relates to a method of controlling phytopathogenic fungi and/or undesired plant growth and/or undesired insect or mite attack and/or for regulating the growth of plants.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: July 5, 2022
    Assignee: BASF SE
    Inventors: Klaus Kolb, Katja Marxer, Anja Simon, Rainer Berghaus
  • Patent number: 11241427
    Abstract: Disclosed are compounds useful for alteration of NR2F6 activity. In some embodiments of the invention compounds disclosed are utilized for stimulation of NR2F6 activity, alone, or in combination with PKC activation. In other embodiments, the invention teaches use of compounds for inhibition of NR2F6 activation. Stimulation of NR2F6 within the context of the invention is useful, intra alia, for induction of immune inhibition, or stimulation of cellular proliferation without significant induction of differentiation. Inhibition of NR2F6 is desired in situations where the practitioner of the invention seeks to augment immune response, or induce cellular differentiation. In another embodiment, inhibition of NR2F6 expression is desired in situations where inhibition of cancer or cancer stem cells is needed.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: February 8, 2022
    Assignee: KCL Therapeutics, Inc.
    Inventors: David Koos, Thomas Ichim
  • Patent number: 11236042
    Abstract: A cooling agent composition includes a methyl menthol derivative represented by the following general formula (1). In the formula (1), a symbol * indicates an asymmetric carbon atom, X represents a hydrogen atom or a substituent, and Y represents an aryl group having 6 to 20 carbon atoms which may have a substituent.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: February 1, 2022
    Assignee: TAKASAGO INTERNATIONAL CORPORATION
    Inventors: Hisanori Itoh, Takaji Matsumoto, Tomoharu Sato, Makoto Harada, Masaya Otake, Masashi Otsuka
  • Patent number: 11097009
    Abstract: The present invention provides: a histone modification control agent for activating expression of a specific gene, i.e., a complex including a histone acetylation enzyme activator useful as an agent for activating a specific gene, and a polyamide for recognizing a regulatory region of a target gene; and a method for manufacturing the same. This complex specifically activates a group of genes relating to maintenance and/or differentiation of stem cells or precursor cells.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: August 24, 2021
    Assignee: KYOTO UNIVERSITY
    Inventors: Hiroshi Sugiyama, Toshikazu Bando
  • Patent number: 10953007
    Abstract: The present invention includes compounds useful as modulators of TRPM8, such as compounds of Formula (I) and the subgenus and species thereof; personal products containing those compounds; and the use of those compounds and the personal products, particularly the use of increasing or inducing chemesthetic sensations, such as cooling or cold sensations.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: March 23, 2021
    Assignee: Firmenich Incorporated
    Inventors: Chad Priest, Alain Noncovich, Andrew Patron, Jane Ung
  • Patent number: 10836821
    Abstract: There is disclosed an improved ADC (antibody drug conjugate) type composition having at least two different drug payloads conjugated to a single targeting protein. More specifically, the present disclosure attaches a first drug conjugate to a dual Cysteine residue on a targeting protein and a second drug conjugate with a different drug to a Lys residue on the targeting protein.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: November 17, 2020
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Zhenwei Miao, Gang Chen, Tong Zhu, Alisher B. Khasanov, Yufeng Hong, Hong D. Zhang, Alexander Chucholowski
  • Patent number: 10774120
    Abstract: The disclosure pertains to conformational epitopes in A-beta, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: September 15, 2020
    Assignee: The University of British Columbia
    Inventors: Neil R. Cashman, Steven S. Plotkin
  • Patent number: 10759837
    Abstract: The disclosure pertains to epitopes identified in A-beta including conformational epitopes, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: September 1, 2020
    Assignee: The University of British Columbia
    Inventors: Neil R. Cashman, Steven S. Plotkin
  • Patent number: 10526307
    Abstract: Disclosed are compounds, for example, compounds of formula (I), (Formula (I) wherein R, R0, R1-R8, n, X, Y, Y?, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: January 7, 2020
    Assignee: ADT Pharmaceuticals, LLC
    Inventors: Gary A. Piazza, Xi Chen, Adam B. Keeton, Michael R. Boyd
  • Patent number: 10449167
    Abstract: The invention relates to a kind of medicinal salts of polyamine derivatives, preparation method and use thereof in preparation of a drug for treating sepsis. These novel compounds have good antagonistic action on a plurality of pathogen-associated molecular patterns that induce sepsis, such as bacterial lipopolysaccharide (endotoxin), bacterial genomic DNA, peptidoglycan, lipoteichoic acid, virus RNA, and zymosan, and can be used for preparation of a drug for treating sepsis.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: October 22, 2019
    Assignee: Chongqing Antixin Biotechnology Co., LTD.
    Inventors: Yue Zheng, Jun Deng, Qingguang Liu
  • Patent number: 10052335
    Abstract: Methods for treating neurodegeneration and/or myelination in patients are disclosed comprising treating the patient with a progestin compound which exerts binding to progesterone receptors and elicits progesterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing androgen or glucocorticoid biological responses at a dosage sufficient to prevent or reduce neurodegeneration. The progestin compound preferably comprises 16-methylene-17?-acetoxy-19-norpregn-4-ene-3,20-dione, and the methods include combining the progestin compound with an estrogen compound to provide both contraception and treatment for myelin repair and neurodegeneration.
    Type: Grant
    Filed: October 19, 2010
    Date of Patent: August 21, 2018
    Assignee: The Population Council, Inc.
    Inventors: Regine Sitruk-Ware, Michael Maria Helmut Schumacher, Roberta Brinton, Martine El-Etr, Abdelmouman Ghoumari, Rachida Guennoun
  • Patent number: 9883997
    Abstract: The invention is directed to a cosmetic composition and the precursor thereof. The composition has solid agent and liquid agent, both of which are cosmetic benefit ingredients. The solubility of solid agents in liquid agents in the inventive compositions is enhanced in the presence of a tricyclodecane amide.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: February 6, 2018
    Assignee: Conopco, Inc.
    Inventors: Bijan Harichian, Teanoosh Moaddel, Ian Stuart Cloudsdale, Van Au, Jianming Lee, John Kenneth Dickson, Jr.
  • Patent number: 9381173
    Abstract: Isolated stereoisomeric forms of the compound (S)2-N(3-O-(propan 2-ol) -1-propyl-4-hydroxybenzene)-3-phenylpropylamide and uses in the treatment of pain.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: July 5, 2016
    Assignee: Novaremed Ltd.
    Inventor: Eliahu Kaplan
  • Patent number: 9301940
    Abstract: The invention features compounds that have antibacterial activity, their use for the treatment of bacterial infections, screening methods that use whole animals or plant seedlings to identify compounds that inhibit a pathogen in the animal or plant, and screening methods to identify compounds that increase the lifespan of an organism.
    Type: Grant
    Filed: June 18, 2007
    Date of Patent: April 5, 2016
    Assignees: The General Hospital Corporation, Northeastern University
    Inventors: Frederick M. Ausubel, Kim Lewis, Terence I. Moy, Suresh Gopalan
  • Patent number: 9204638
    Abstract: The present invention relates to a method of increasing yield of a plant. This method involves applying to a plant and/or area of cultivation thiophanate methyl and an isolated hypersensitive response elicitor protein or polypeptide fragment, wherein said applying is carried out under conditions effective to induce a synergistic yield from the plant. The present invention also relates to a composition comprising a liquid or solid carrier, thiophanate methyl, and an isolated hypersensitive response elicitor protein or polypeptide fragment.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: December 8, 2015
    Assignee: Plant Health Care, Inc.
    Inventor: Zhongmin Wei
  • Patent number: 9199917
    Abstract: Compounds for use in the treatment or prophylaxis of pain, including acute and chronic pain (e.g., nociceptive pain, neuropathic pain, headaches, migraine), represented by general formula (I) in which: the dotted line represents a single or a double bond; and R5 and R5? are independently —H, —OH or —OR6, where R6 is a linear or branched C1-C4 alkyl; X is -0-, —CH2O—, —CH2CH2O—, —CH(CH3)CH2O— or —CH2CH(CH3)O—; Z is —CH2CH2O—, —CH(CH3)CH2O— or —CH2CH(CH3)O—; m is an integer of O or 1; and n is an integer of 0-50. The compounds of the invention are also effective for reducing inflammation and may be used alone or in combination with other analgesics.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: December 1, 2015
    Assignee: Novaremed Limited
    Inventor: Eliahu Kaplan
  • Patent number: 9169196
    Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: October 27, 2015
    Assignee: Edison Pharmaceuticals, Inc.
    Inventors: Orion D. Jankowski, Kieron E. Wesson, Paul Mollard, William D. Shrader
  • Patent number: 9132111
    Abstract: Disclosed are topical antimicrobial compositions. The compositions are useful for disinfecting and treating microbial infections of the skin or mucosa of humans and animals.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: September 15, 2015
    Inventors: Kewang Lu, Hoshun Luk, Lei Zhang
  • Patent number: 9051240
    Abstract: Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them are useful as sodium and/or calcium channel modulators for preventing, alleviating and curing pathologies wherein the above mechanisms play a pathological role. The compounds may be particularly useful for the prevention, alleviation, and curing of, for example, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: June 9, 2015
    Assignee: Newron Pharmaceuticals S.P.A.
    Inventors: Piero Melloni, Alessandra Restivo, Emanuela Izzo, Simona Francisconi, Elena Colombo, Cibele Sabido-David
  • Publication number: 20150133406
    Abstract: Control or repellency of biting arthropods, particularly biting insects, is accomplished by bringing the biting arthropods into contact with combinations of compounds identical or related to those found on human/animal skin or in plants acting synergistically with one another, or in combination with conventional repellents like DEET®, para-menthane-3,8-diol (PMD), sec-butyl-2-(2-hydroxyethyl) piperidine carboxylate (“Picaridin”), or other nitrogen containing repellents selected from amines, amides and nitrogen containing heterocyclic compounds, or any synergistic combination of DEET®, PMD, Picaridin, or other nitrogen containing repellents selected from amines, amides and nitrogen containing heterocyclic compounds.
    Type: Application
    Filed: November 13, 2014
    Publication date: May 14, 2015
    Inventor: Robert H. BEDOUKIAN
  • Publication number: 20150133540
    Abstract: Control or repellency of mosquitoes is accomplished by bringing the insects into contact with at least one of the compounds of the structure (I) wherein R is selected from —OH, ?O, —OC(O)R4, —OR6, —(OR6)2, wherein each R6 is independently selected from an alkyl group containing from 1 to 4 carbon atoms and R4 is a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; X is O or CH2, with the proviso that when X is O R can only be ?O; each Z is independently selected from (CH) and (CH2); y is a numeral selected from 1 and 2; R1 is selected from H or a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; R2 is selected from H and a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to three double bonds and from 1 to 15 carbon atoms; R3 is selected from the group consisting of H and a branched or straight chain, satur
    Type: Application
    Filed: April 30, 2013
    Publication date: May 14, 2015
    Inventor: Robert H. Bedoukian
  • Patent number: 9029293
    Abstract: An inhibitor for tobacco axillary bud growth, the inhibitor containing one or more cell division inhibitors selected from pyridine-based compounds and benzamide-based compounds. This inhibitor may further include an aliphatic alcohol having 6 to 20 carbon atoms in combination with the one or more cell division inhibitors.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: May 12, 2015
    Assignee: SDS Biotech K.K.
    Inventors: Motoki Tanaka, Keijitsu Tanaka, Takeshi Shibuya, Eiji Ikuta, Kotaro Yoshinaga, Yuki Yamaguchi
  • Publication number: 20150126493
    Abstract: The invention provides bicyclic sulfone compounds, pharmaceutical compositions, methods of inhibiting RORy activity, reducing the amount of iL-17 in a subject, and treating immune disorders and inflammatory disorders using such bicyclic sulfone compounds. Another aspect of the invention provides a method of treating a subject suffering from a medical disorder. The method comprises administering to the subject a therapeutically effective amount of one or more bicyclic sulfone compounds described herein. In certain other embodiments, the disorder is rheumatoid arthritis.
    Type: Application
    Filed: May 3, 2013
    Publication date: May 7, 2015
    Inventors: Thomas D. Aicher, Kenneth J. Barr, Vladimir Simov, Willam D. Thomas, Peter L. Toogood, Chad A. Van Huis
  • Publication number: 20150126572
    Abstract: A method for treating a patient having ASD is disclosed. The method includes administering to the patient a plurality of comestible units, e.g., cookies, cumulatively comprising a therapeutically effective amount of inositol. The method may further include administering to the patient a therapeutically effective amount of an alpha-2 adrenergic agonist in an extended release dosage form.
    Type: Application
    Filed: January 14, 2015
    Publication date: May 7, 2015
    Inventor: Richard Louis Price
  • Publication number: 20150111749
    Abstract: Methods and compositions for controlling plant pests, particularly weeds and/or plant phytopathogens using sarmentine and/or analogs thereof are disclosed.
    Type: Application
    Filed: December 31, 2014
    Publication date: April 23, 2015
    Inventors: Huazhang Huang, Ratnakar Asolkar
  • Publication number: 20150105349
    Abstract: Short-chain 2- to 3-carbon alcohols are used as solvents for cooling agents in the preparation of topical therapeutic and cosmetic formulations. Some of these alcohols, especially ethanol, inhibit the ability of the cooling agent to activate its target receptor. In one embodiment of this invention, (R)-1,2-propanediol is used as an alcoholic solvent for the topical delivery of cooling agents to biological surfaces. This (R)-1,2-propanediol enantiomer has a minimum inhibitory effect on cooling with respect to standard 2- to 3-carbon alcoholic solvents, and functions to substantially protect the agents cooling activity from inhibition when in the presence of a short-chain alcohol such as ethanol.
    Type: Application
    Filed: August 19, 2013
    Publication date: April 16, 2015
    Inventor: Edward T. Wei
  • Patent number: 8993581
    Abstract: Disclosed are methods of treating viral disorders via the administration of an inducing agent and an anti-viral agent. In one embodiment, the inducing agent and the anti-viral agent are administered for about five days, and the anti-viral agent is subsequently administered without the inducing agent for an additional period of about sixteen days for a total cycle of about 21 days.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: March 31, 2015
    Assignee: Trustees of Boston University
    Inventors: Susan Perrine, Douglas Faller
  • Publication number: 20150087712
    Abstract: The present invention relates to methods for reducing testosterone levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC), metastatic castration resistant prostate cancer (mCRPC), and methods of reducing high or increasing PSA levels and/or increasing SHBG levels in a subject suffering from prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC) and metastatic castration resistant prostate cancer (mCRPC). The compounds of this invention suppress free or total testosterone levels despite castrate levels secondary to ADT and reduce high or increasing PSA levels. This reduction in testosterone levels may be used to treat prostate cancer, advanced prostate cancer, CRPC and mCRPC without causing bone loss, decreased bone mineral density, increased risk of bone fractures, increased body fat, hot flashes and/or gynecomastia.
    Type: Application
    Filed: October 24, 2014
    Publication date: March 26, 2015
    Inventors: James T. Dalton, Mitchell S. Steiner, Christopher C. Coss, Robert H. Getzenberg
  • Publication number: 20150080473
    Abstract: Compounds for use in the treatment or prophylaxis of pain, including acute and chronic pain (e.g., nociceptive pain, neuropathic pain, headaches, migraine), represented by general formula (I) in which: the dotted line represents a single or a double bond; and R5 and R5? are independently —H, —OH or —OR6, where R6 is a linear or branched C1-C4 alkyl; X is -0-, —CH2O—, —CH2CH2O—, —CH(CH3)CH2O— or —CH2CH(CH3)O—; Z is —CH2CH2O—, —CH(CH3)CH2O— or —CH2CH(CH3)O—; m is an integer of O or 1; and n is an integer of 0-50. The compounds of the invention are also effective for reducing inflammation and may be used alone or in combination with other analgesics.
    Type: Application
    Filed: October 7, 2014
    Publication date: March 19, 2015
    Inventor: Eliahu Kaplan
  • Publication number: 20150045213
    Abstract: Compounds of the formula (I), in which the substituents are as defined in claim 1, are suitable for use as nematicides.
    Type: Application
    Filed: March 6, 2013
    Publication date: February 12, 2015
    Inventors: Anthony Cornelis O'Sullivan, Olivier Loiseleur, Roman Staiger, Torsten Luksch, Thomas Pitterna
  • Publication number: 20150023889
    Abstract: Disclosed are compounds, compositions, and methods relating to fluoride aptamers, fluoride-responsive riboswitches, fluoride-regulated expression constructs, fluoride transporters, nucleic acids encoding fluoride transporters, expression constructs encoding fluoride transporters, and cells containing or including any combination of these.
    Type: Application
    Filed: September 17, 2012
    Publication date: January 22, 2015
    Inventors: Ronald Breaker, Jenny Baker, Narasimhan Sudarsan, Zasha Weinberg, Adam Roth, Tyler Ames, James Nelson
  • Publication number: 20150023921
    Abstract: The present invention relates to novel compositions having anti-viral activity and in particular it relates to synergistic compositions active against Hepatitis C virus (HCV). The invention also relates to methods for retarding, reducing or otherwise inhibiting HCV growth and/or functional activity.
    Type: Application
    Filed: April 3, 2014
    Publication date: January 22, 2015
    Applicant: BIOTRON LIMITED
    Inventors: Gary Dinneen EWART, Carolyn Anne LUSCOMBE, Michelle MILLER
  • Publication number: 20150010635
    Abstract: Controlled release particles are obtained by dissolving a hydrophobic antibiotic compound with a hydrophobic polymerizable vinyl monomer to prepare a hydrophobic solution, blending water with an emulsifier to prepare an aqueous emulsifier solution, emulsifying the hydrophobic solution in the aqueous emulsifier solution, and polymerizing the polymerizable vinyl monomer by mini-emulsion polymerization in the presence of a polymerization initiator, thereby producing a polymer containing an antibiotic compound and having an average particle size of below 1 ?m.
    Type: Application
    Filed: December 27, 2012
    Publication date: January 8, 2015
    Applicant: Japan EnviroChemicals, Ltd.
    Inventors: Junji Oshima, Hideaki Inoue
  • Publication number: 20150011516
    Abstract: Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.
    Type: Application
    Filed: July 21, 2014
    Publication date: January 8, 2015
    Inventors: Leonard M. Neckers, Marc B. Cox, Jane B. Neckers, Yeong Sang Kim, Aki Iwai, Yangmin Ning, Johanny Tonos de Leon, Heather A. Balsiger, Robert Fletterick
  • Patent number: 8927605
    Abstract: The invention relates to a TRPM8 modulator for achieving a cooling effect on the skin or a mucous membrane.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: January 6, 2015
    Assignees: Symrise AG, BASF SE
    Inventors: Thomas Subkowski, Michael Backes, Heiko Oertling, Arnold Machinek, Hubert Loges, Ulrike Simchen, Horst Surburg, Claus Bollschweiler, Jens Wittenberg, Wolfgang Siegel
  • Publication number: 20150005320
    Abstract: The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof wherein X, Y, A, Z, L and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions and immune disorders.
    Type: Application
    Filed: September 27, 2013
    Publication date: January 1, 2015
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Yu Xie, Mats Holmqvist, Jerome Mahiou, Mitsunori Ono, Lijun Sun, Shoujun Chen, Shijie Zhang, Jun Jiang, Dinesh Chimmanamada, Chih-Yi Yu
  • Publication number: 20140378461
    Abstract: Compounds of the formula (I), in which the substituents are as defined in claim 1, are suitable for use as nematicides.
    Type: Application
    Filed: February 14, 2013
    Publication date: December 25, 2014
    Applicant: SYNGENTA PARTICIPATIONS AG
    Inventors: Anthony Cornelius O'Sullivan, Olivier Loiseleur, Daniel Stierli, Torsten Luksch, Thomas Pitterna
  • Patent number: 8916550
    Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
    Type: Grant
    Filed: November 15, 2006
    Date of Patent: December 23, 2014
    Assignee: Hydra Biosciences, Inc.
    Inventors: Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, Jr., Magdalene M. Moran, Amy Ripka, Dennis John Underwood, Manfred Weigele, Xiaoguang Zhen, Anu Mahadevan, Peter Meltzer
  • Publication number: 20140356290
    Abstract: Methods for therapeutic renal denervation are disclosed herein. One aspect of the present application, for example, is directed to methods that block, reduce and/or inhibit renal sympathetic nerve activity to achieve a reduction in central sympathetic tone. Renal sympathetic nerve activity may be altered or modulated along the afferent and/or efferent pathway. The achieved reduction in central sympathetic tone may carry several therapeutic benefits across many disease states.
    Type: Application
    Filed: June 6, 2014
    Publication date: December 4, 2014
    Inventors: Neil Barman, Howard Levin, Paul Sobotka, Mark Gelfand
  • Publication number: 20140350099
    Abstract: Compounds for use in the treatment or prophylaxis of pain, including acute and chronic pain (e.g., nociceptive pain, neuropathic pain, headaches, migraine), represented by general formula I: in which: the dotted line represents a single or a double bond; and R5 and R5? are independently —H, —OH or —OR6, where R6 is a linear or branched C1-C4 alkyl; X is —CH2O—; Z is —CH2CH2O—, —CH(CH3)CH2O— or —CH2CH(CH3)O—; m is 1; and n is an integer of 1-5. The compounds of the invention are also effective for reducing inflammation and may be used alone or in combination with other analgesics.
    Type: Application
    Filed: July 21, 2014
    Publication date: November 27, 2014
    Inventor: Eliahu Kaplan
  • Publication number: 20140343108
    Abstract: The present invention belongs to the field of natural medicine and pharmaceutical chemistry, and specifically relates to novel amidated derivatives of oleanolic acid according to formula (I) or a pharmaceutically acceptable salt thereof, to a process for the preparation of these compounds, compositions containing such compounds and their use in preparing antineoplastic medicaments.
    Type: Application
    Filed: November 30, 2012
    Publication date: November 20, 2014
    Inventors: Frank Rong, Rongzhen Xu, Fuwen Xie, Hongxi Lai
  • Patent number: 8889731
    Abstract: This invention relates to compositions of one or more compounds that incorporate one or more allyl sulfide, allyl disulfide or allyl polysulfide moieties, or one or more allyl sulfide, allyl disulfide or allyl polysulfide moieties and one or more hydroxyl groups, used in effective amount in formulations, including emulsions, to repel blood-feeding ectoparasitic arthropods, including mosquitoes, and to deter them from landing and feeding when applied to the skin, clothing or environment of animals, including humans. Said compounds can include, but are not limited to, 8-allyl-sulfanyloctan-1-ol. This invention also relates to compositions comprising one or more of said compounds in further combination with other arthropod repellent and deterrent compounds, including vanillin. These compounds may be formulated with inert ingredients to form a liquid, gel, paste, soap, spray, aerosol or powder.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: November 18, 2014
    Assignee: Contech Enterprises Inc.
    Inventors: Regine M. Gries, Gerhard G. Gries, Grigori Khaskin, Norman Avelino, Cory Campbell
  • Patent number: 8883853
    Abstract: Compounds for use in the treatment or prophylaxis of pain, including acute and chronic pain (e.g., nociceptive pain, neuropathic pain, headaches, migraine), represented by general formula (I) in which: the dotted line represents a single or a double bond; and R5 and R5? are independently —H, —OH or —OR6, where R6 is a linear or branched C1-C4 alkyl; X is -0-, —CH2O—, —CH2CH2O—, —CH(CH3)CH2O— or —CH2CH(CH3)O—; Z is —CH2CH2O—, —CH(CH3)CH2O— or —CH2CH(CH3)O—; m is an integer of O or 1; and n is an integer of 0-50. The compounds of the invention are also effective for reducing inflammation and may be used alone or in combination with other analgesics.
    Type: Grant
    Filed: March 6, 2009
    Date of Patent: November 11, 2014
    Assignee: Novaremed Limited
    Inventor: Eliahu Kaplan
  • Publication number: 20140329860
    Abstract: Methods of treating or suppressing oxidative stress diseases including mitochondrial diseases, impaired energy processing disorders, neurodegenerative diseases and diseases of aging are disclosed, as well as compounds useful in the methods of the invention, such as 2-substituted-p-quinone derivatives as disclosed herein.
    Type: Application
    Filed: March 24, 2014
    Publication date: November 6, 2014
    Applicant: Edison Pharmaceuticals, Inc.
    Inventors: Andrew W. Hinman, Kieron E. Wesson, Orion D. Jankowski, Paul Mollard, William D. Shrader, Christopher R. Cornell
  • Patent number: 8877815
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, B, X, m and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of compounds of the invention, and a combination of pharmacologically active agents and a compound of the invention.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: November 4, 2014
    Assignee: Novartis AG
    Inventors: Rajeshri Ganesh Karki, Toshio Kawanami, Gary Michael Ksander, Qian Liu, Muneto Mogi, Nikolaus Schiering, Robert Sun
  • Patent number: 8877754
    Abstract: The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: November 4, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Gerald Juergen Roth, Martin Fleck, Heike Neubauer, Bernd Nosse
  • Publication number: 20140323520
    Abstract: The present disclosure provides methods of increasing proliferation of adult salivary stem cells. The methods include contacting adult salivary stem cells in vivo, in vitro, or ex vivo with an aldehyde dehydrogenase (ALDH) agonist. Increasing proliferation of adult salivary stem cells can be carried out to provide for an increase in the number of adult salivary stem cells in an indi vidual undergoing radiotherapy for head and neck cancer.
    Type: Application
    Filed: April 26, 2012
    Publication date: October 30, 2014
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Che-Hong Chen, Daria Mochly-Rosen, Quynh-Thu Le
  • Publication number: 20140323561
    Abstract: Control and repellency of biting flies, house flies, ticks, ants, fleas, biting midges, cockroaches, spiders and stink bugs is obtained by contact of the insects with at least one of the compounds of the structure (I).
    Type: Application
    Filed: October 21, 2013
    Publication date: October 30, 2014
    Inventor: Robert H. Bedoukian